Is there significant improvement in neonatal outcome after treating pPROM mothers with amnio-infusion?
The aim of this study was to determine the effects of amnio-infusion treatment on fetal and neonatal mortality and neonatal pulmonary development in women with singleton pregnancies and premature rupture of the membranes occurring at a gestational age of <26 weeks and who had severe oligohydramnios. The treated group of 45 consenting women received serial amnio-infusion and was compared with the control group of 44 women who underwent waiting treatment. Our study confirmed a higher number of live births in the treated group, especially in cases with a gestational age at rupture (GAR) of <20 weeks. Furthermore, even if GAR is an important factor for predicting pulmonary hypoplasia, amnio-infusion treatment reduces the probability of pulmonary hypoplasia. In fact, over 20 weeks, amnio-infusion treatment significantly reduces the risk of pulmonary hypoplasia even if normal lung development cannot be guaranteed.
De Carolis
Maria Pia
MP
Division of Neonatology, Catholic University 'Sacred Heart', Rome, Italy. piadc@katamail.com
Romagnoli
Costantino
C
De Santis
Marco
M
Piersigilli
Fiammetta
F
Vento
Giovanni
G
Caruso
Alessandro
A
D000328:Adult; D000653:Amniotic Fluid; D001724:Birth Weight; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000150:complications / Q000628:therapy*; D005865:Gestational Age; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D007234:Infant, Premature; D016015:Logistic Models; D016104:Oligohydramnios / Q000150:complications; D011247:Pregnancy; D011256:Pregnancy Outcome